Biocon and Genentech reach global Pebrilzo biosimilar patent settlement establishing launch dates
Biocon and Genentech have reached a global patent settlement and licence agreement establishing planned launch windows for Pebrilzo, Biocon's pertuzumab biosimilar to Perjeta.
The agreement resolves pending patent disputes and permits Biocon to launch Pebrilzo in the EU and UK from the first quarter of 2027, in the United States from the third quarter of 2028 and in other territories according to agreed timelines.
The settlement provides greater commercial planning certainty for the proposed oncology biosimilar, although actual launches remain subject to applicable regulatory approvals and market access requirements.
Field | Content |
Article Type | Deals |
Companies | Biocon; Genentech |
Deal Type | Global patent settlement and licence agreement |
Product | Pebrilzo |
Molecule | Pertuzumab |
Reference Product | Perjeta |
Therapeutic Area | Oncology; HER2-targeted breast cancer treatment |
Agreement Scope | Resolution of patent disputes and establishment of licensed biosimilar launch dates |
EU and UK Launch Window | From Q1 2027 |
US Launch Window | From Q3 2028 |
Other Territories | During 2026–2028 or earlier in certain circumstances |
Financial Terms | Not disclosed in supplied summary |
Regulatory Status | Commercial launch remains subject to applicable marketing approvals |
Geography | Global; including European Union, United Kingdom and United States |
What Happened | Biocon and Genentech agreed to a global patent settlement permitting specified future launch windows for Pebrilzo. |
Why It Matters | The agreement reduces patent-related uncertainty and establishes a clearer commercial pathway for a proposed pertuzumab biosimilar. |
Strategic Rationale | Biocon secures licensed market-entry dates while Genentech resolves outstanding intellectual property disputes. |
Key Takeaway | The settlement establishes commercial launch rights but does not itself constitute regulatory approval of Pebrilzo. |
What to Watch | Regulatory decisions, launch execution, reimbursement arrangements and competitive dynamics in pertuzumab biosimilars. |
Primary Source | Biocon announcement |
Relevant Date | 14 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios